Clinical Trial Search

Phase 3 N=1,200 Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Primary: Geometric Mean Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects — 12; 15; 16; 14 Titers

Novartis Vaccines Results Jan 2013 2.6% serious AE View details

Phase 3 N=382 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

Diabetes Mellitus · Macular Edema

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 33.6; 45.7; 12.3 Percentage of patients…

Genentech, Inc. Results Jan 2013 41.0% serious AE View details

Phase 3 N=135 Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Primary: Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV). — 22; 23; 624; 199 Titer

Novartis Vaccines Results Jan 2013 0.0% serious AE View details

Phase 3 N=377 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)

Diabetes Mellitus · Macular Edema

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…

Genentech, Inc. Results Jan 2013 40.7% serious AE View details

Phase 3 N=3,604 Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

Influenza

Primary: Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children — 407; 477; 768; 1293 Titers

Novartis Results Jan 2013 0.4% serious AE View details

Phase 3 N=11,404 Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Primary: Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains — 7; 9; 44; 2 Subjects — p=<0.001

Novartis Vaccines Results Jan 2013 1.0% serious AE View details

Phase 3 N=2,418 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Primary: Safety Assessed by Adverse Events — 8.6; 7.8; 5.9; 4.9 percentage of participants

MEDA Pharma GmbH & Co. KG Results Jan 2013 18.9% serious AE View details

Phase 3 N=383 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Pulmonary Arterial Hypertension

Primary: Frequently Reported (15% or More Overall) Adverse Events by Severity — 1; 20; 36; 0 participants

Gilead Sciences Results Jan 2013 53.5% serious AE View details

Phase 3 N=205 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain

Acute Ankle Sprain

Primary: Pain on Movement — 25.6; 61.2 mm

Novartis Results Jan 2013 0.5% serious AE View details

Phase 3 N=583 Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Epilepsy

Primary: Percentage of Participants Remaining in the Study at Each Visit — 95.6; 93.7; 87.6; 84.2 Percentage of Participants

Eisai Inc. Results Jan 2013 5.3% serious AE View details

Phase 3 N=310 Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

Pulmonary Hypertension

Primary: 6-minute Walk Distance (6MWD) — 370; 365; 15; 11 meters — p=0.089

United Therapeutics Results Jan 2013 14.8% serious AE View details

Phase 3 N=416 RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Metastatic Renal Cell Carcinoma

Primary: Progressive Free Survival (PFS) in Patients Who Receive RAD001 Plus Best Supportive Care(BSC) Versus Patients Who Receive Matching Placebo Plus BSC — 4.90; 1.87 Months

Novartis Pharmaceuticals Results Jan 2013 51.6% serious AE View details

Phase 3 N=2,235 Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly

Influenza

Primary: Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine — 78; 73; 47; 51 Participants

Novartis Vaccines Results Jan 2013 2.9% serious AE View details

Phase 3 N=611 A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Arthritis, Rheumatoid

Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3 — 59.75; 65.70; 26.67 percentage of participants — p=<0.0001

Pfizer Results Jan 2013 2.0% serious AE View details

Phase 3 N=399 Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Arthritis, Rheumatoid

Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3 — 41.67; 48.12; 24.43 percentage of participants — p=<0.0001

Pfizer Results Jan 2013 3.3% serious AE View details